---
title: "CapsoVision Stockholders Reelect Directors, Ratify 2026 Auditor"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289630049.md"
description: "CapsoVision Inc. held its 2026 Annual Meeting, reelecting directors Joanne Imperial, Wen-Herng King, and Michele Harari, and ratifying Baker Tilly US, LLP as auditor. The company operates in medical technology, focusing on capsule endoscopy systems. While analysts rate the stock a Buy with an $11 target, TipRanks' AI suggests Neutral due to heavy losses despite revenue growth."
datetime: "2026-06-12T18:27:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289630049.md)
  - [en](https://longbridge.com/en/news/289630049.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289630049.md)
---

# CapsoVision Stockholders Reelect Directors, Ratify 2026 Auditor

CapsoVision, Inc. ( (CV) ) has shared an update.

CapsoVision Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders voted on director elections and auditor ratification. The meeting outcomes confirm continuity in board leadership and financial oversight, signaling stability in corporate governance for investors.

Stockholders re-elected Joanne Imperial, M.D., Wen-Herng (Henry) King, and Michele Harari as Class I Directors to serve until the 2029 annual meeting, with strong support indicated by the vote totals. Shareholders also approved the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the 2026 fiscal year, reinforcing confidence in the company’s audit and reporting framework.

The most recent analyst rating on (CV) stock is a Buy  
with a $11.00 price target.  
To see the full list of analyst forecasts on CapsoVision, Inc. stock,  
see the CV Stock Forecast page.

**Spark’s Take on CV Stock**

According to Spark, TipRanks’ AI Analyst, CV is a Neutral.

The score is held back primarily by heavy ongoing losses and large cash burn despite strong revenue growth and improving operations. Technicals are supportive with positive momentum, and recent corporate updates are constructive on product development/regulatory progress, but valuation remains pressured due to negative earnings.

To see Spark’s full report on CV stock,  
click here.

**More about CapsoVision, Inc.**

CapsoVision Inc. operates in the medical technology sector, focusing on diagnostic imaging solutions such as capsule endoscopy systems. The company targets healthcare providers and hospitals, aiming to improve gastrointestinal diagnostics through minimally invasive devices and related services.

**Average Trading Volume:** 255,305

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $344.2M

### Related Stocks

- [CV.US](https://longbridge.com/en/quote/CV.US.md)

## Related News & Research

- [CMR announces availability of 2Q26 quarterly report certification letter](https://longbridge.com/en/news/294541304.md)
- [Hoya launches strategic review of PENTAX Medical endoscope business, including possible sale](https://longbridge.com/en/news/294454626.md)
- [Acosta Verde announces shareholder meeting](https://longbridge.com/en/news/294102460.md)
- [HEDGE FLOW-Hedge fund bets on rising US healthcare stocks near 5-year high, Goldman says](https://longbridge.com/en/news/293938581.md)
- [Convertidora Industrial publishes sustainability and climate report](https://longbridge.com/en/news/294419158.md)